Treatment Of Peritoneal Carcinomatosis
M. Hornung, H. Schlitt
Published 2018 · Medicine
Download PDFAnalyze on Scholarcy
Peritoneal carcinomatosis is defined as a metastatic spread of a malignant tumor into the peritoneal cavity. Previously, patients suffering from this kind of malignant peritoneal dissemination were supposed to have a very poor prognosis . However, this situation has improved over the last decade due to the implementation of new systemic and surgical treatment strategies.
This paper references
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
P. Piso (2004)
5‐fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer: Decreased toxicity in combined treatment with 5‐fluorouracil administration through the intraperitoneal route
P. Sugarbaker (1986)
In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.
B. Barlogie (1980)
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
P. Sugarbaker (2006)
Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy
D. L. Chan (2012)
Early postoperative intraperitoneal chemotherapy for gastric cancer.
W. Yu (1991)
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
D. Armstrong (2006)
Peritoneal carcinomatosis from non‐gynecologic malignancies
B. Sadeghi (2000)
A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin
Christopher Cao (2009)
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr
M. Markman (2001)
Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies
M. Koppe (2006)
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma.
O. Glehen (2003)
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.
G. Eltabbakh (1999)
Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.
S. Sangisetty (2012)
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
D. Elias (2009)
A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process
N. Carr (2016)
Treatment goals in ovarian cancer
R. Ozols (2005)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial
X. Yang (2011)
Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin.
K. Wallner (1987)
Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality
T. Chua (2009)
A Comparative Study of Complete Cytoreductive Surgery Plus Intraperitoneal Chemotherapy to Treat Peritoneal Dissemination From Colon, Rectum, Small Bowel, and Nonpseudomyxoma Appendix
D. Elias (2010)
Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis
J. Pelz (2009)
Long-term Survival Following Treatment of Pseudomyxoma Peritonei: An Analysis of Surgical Therapy
T. Miner (2005)
Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors
D. Chu (1989)
Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer
R. Ozols (1982)
Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites
Reese W Randle (2013)
Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.
V. Fernandez-Trigo (1996)
Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei
M. Deraco (2004)
Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy
O. Glehen (2010)
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
P. Sugarbaker (1990)
Pseudomyxoma Peritonei Long‐Term Patient Survival with an Aggressive Regional Approach
D. Gough (1994)
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
T. Chua (2012)
Pseudomyxoma Peritonei of Appendiceal Origin: A Clinicopathologic Analysis of 101 Patients Uniformly Treated at a Single Institution, With Literature Review
Robert F Bradley (2006)
Efficacy and Safety of Intraoperative Peritoneal Hyperthermic Chemotherapy for Advanced Gastric Cancer Patients with Serosal Invasion
Z. Zhu (2006)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
Patient Selection for a Curative Approach to Carcinomatosis
Pompiliu Piso (2009)
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
D. Alberts (1996)
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
A. Feldman (2003)
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study
D. Hompes (2012)
This paper is referenced by
Critical considerations for targeting colorectal liver metastases with nanotechnology
Usman Arshad (2019)
Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
P. Sammartino (2016)